IRISYS: Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS

Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast Scheduled for 11:00 a.m. Eastern on Thursday, August 19, 2021 EXTON, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that company management will host a webcast to discuss the company's recently announced acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. The webcast will be held at 11:00 a.m. Eastern on Thursday, August 19, 2021. During the event, Recro's management team will discuss the rationale for its acquisition of IRISYS and provide an overview of the transaction's expected impact on the company's ongoing growth strategy. The discussion will highlight Recro's operations on both the East and West Coast of the U.S., as well as the organization's expanded global client base and enhanced capabilities now spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of dosage forms. To access the webcast, please do so by visiting the "Events" page in the Investor section of the Company's website, Full story available on Benzinga.com